Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Metastatic colorectal cancer (mCRC) remains a highly lethal malignancy although considerable progress has resulted from characterizing molecular alterations such as RAS mutation status and extent of microsatellite instability (MSI) to guide optimal use of available therapies. The availability of gene expression profiling, next generation sequencing technologies, proteomics analysis and other technologies provides high resolution information on individual tumors, including metastatic lesions to better define intra-tumor and inter-tumor heterogeneity. Recent literature applying this information to further customize personalized therapies is reviewed. Current biomarker-based stratification used to select optimal therapy that is personalized to the mutation profile of individual tumors is described. Recent literature using whole exome sequencing of metastatic lesions and primary CRC tumors and other advanced technologies to more fully elucidate the tumor biology specific to mCRC sub-types and to develop more precise therapies that improve outcomes is also reviewed. Keywords: colorectal cancer, metastasis, mutation, whole exome sequencing, targeted therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The increased availability and reduced cost of next-generation sequencing technologies may enable important new targets to be identified [150].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [150]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Colorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880
The repertoire of mutational signatures in human cancer
Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., et al. (2020) · Nature · doi:10.1038/s41586-020-1943-3 · Cited by 3,496
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“oncogenic drivers of metastasis and reveal new therapeutic targets for mCRC and other cancers.(72) In general, sequencing”
BackgroundMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Pan-cancer whole-genome analyses of metastatic solid tumours
Priestley, P., Baber, J., Lolkema, M. P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1689-y · Cited by 1,106 · cited 1×
“mary tumors and metastatic lesions with regard to key driver oncogenic mutations.(73) Divergence, when it occurs, is gen-”
BackgroundSartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
The Chromosomal Instability Pathway in Colon Cancer
Pino, M. S., & Chung, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.065 · Cited by 932
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M. T. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.004 · Cited by 858
Lynch, H., Lynch, P., Lanspa, S., Snyder, C., Lynch, J., & Boland, C. (2009) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01230.x · Cited by 840
Salonga, D. S., Danenberg, K. D., Johnson, M. R., Metzger, R., Groshen, S. G., Tsao-Wei, D. D., Lenz, H.-J., Leichman, C. G., Leichman, L., Diasio, R. B., et al. (2000) · PubMed · Cited by 829
AKT as a Therapeutic Target for Cancer
Song, M., Bode, A. M., Dong, Z., & Lee, M.-H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2738 · Cited by 782
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654 · cited 2×
“cancer (mCRC) and in developing effective targeted therapies tailored to the oncogenic drivers.(6,17) Epidermal”
BackgroundMethodKRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617 · cited 12×
“Genes enriched in SBS1 include HYDIN, C1QB, and COL22A1 which were previously implicated in CRC metastatic progression.87 Somatic copy number alterations (SCNAs) did not significantly differ between mCRC and non-mCRC.”
BackgroundInfluentialBecht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3780 · Cited by 506
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479 · cited 1×
“with acquired resistance to anti-EGFR therapy.(44)”
Molecular Classification and Correlates in Colorectal Cancer
Ogino, S., & Goel, A. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070082 · Cited by 460
Jung, Y.-S., & Park, J.-I. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0380-6 · Cited by 419
Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0348-2 · Cited by 418
Postoperative Adjuvant Chemotherapy or BCG for Colon Cancer: Results From NSABP Protocol C-011
Wolmark, N., Fisher, B., Rockette, H., Redmond, C., Wickerham, D. L., Fisher, E. R., Jones, J., Glass, A., Lerner, H., Lawrence, W., et al. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.1.30 · Cited by 400
Sinicrope, F. A., & Sargent, D. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1469 · Cited by 309
Wang, J., Li, S., Liu, Y., Zhang, C., Li, H., & Lai, B. (2020) · Cancer Medicine · doi:10.1002/cam4.2673 · Cited by 308
Isella, C., Brundu, F., Bellomo, S. E., Galimi, F., Zanella, E., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15107 · Cited by 302
Integrated Omics of Metastatic Colorectal Cancer
Li, C., Sun, Y.-D., Yu, G.-Y., Cui, J.-R., Lou, Z., Zhang, H., Huang, Y., Bai, C.-G., Deng, L.-L., Liu, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.002 · Cited by 297 · cited 3×
“multi-omic analysis may be required to more fully understand metastatic progression and optimize treatments.(76)”
BackgroundInfluentialHeterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123733 · Cited by 262 · cited 1×
“ing may yield ambiguous results with tumor heterogeneity a confounding factor.(22) Further, acquired resistance to anti-EGFR therapy is also a serious concern.”
BackgroundLunenburg, C. A. T. C., van der Wouden, C. H., Nijenhuis, M., Crommentuijn-van Rhenen, M. H., de Boer-Veger, N. J., Buunk, A. M., Houwink, E. J. F., Mulder, H., Rongen, G. A., van Schaik, R. H. N., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-019-0540-0 · Cited by 242
Naba, A., Clauser, K. R., Whittaker, C. A., Carr, S. A., Tanabe, K. K., & Hynes, R. O. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-518 · Cited by 236
Advances in immunotherapy for colorectal cancer: a review
Golshani, G., & Zhang, Y. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820917527 · Cited by 236
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
Ho, C.-C., Liao, W.-Y., Lin, C.-A., Shih, J.-Y., Yu, C.-J., & Chih-Hsin Yang, J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2231 · Cited by 219
Stintzing, S., Wirapati, P., Lenz, H.-J., Neureiter, D., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S., Heintges, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz387 · Cited by 197
Evrard, C., Tachon, G., Randrian, V., Karayan-Tapon, L., & Tougeron, D. (2019) · Cancers · doi:10.3390/cancers11101567 · Cited by 181
Dorard, C., de Thonel, A., Collura, A., Marisa, L., Svrcek, M., Lagrange, A., Jego, G., Wanherdrick, K., Joly, A. L., Buhard, O., et al. (2011) · Nature Medicine · doi:10.1038/nm.2457 · Cited by 167
BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
Caputo, F., Santini, C., Bardasi, C., Cerma, K., Casadei-Gardini, A., Spallanzani, A., Andrikou, K., Cascinu, S., & Gelsomino, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215369 · Cited by 162
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Wang, Q., Shi, Y.-L., Zhou, K., Wang, L.-L., Yan, Z.-X., Liu, Y.-L., Xu, L.-L., Zhao, S.-W., Chu, H.-L., Shi, T.-T., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0776-6 · Cited by 147 · cited 1×
“Activation of the PI3K/Akt pathway, which is frequently mutated in CRC with enrichment in mCRC,(10) also confers resistance to anti-EGFR therapy and to first-line chemotherapy.(38) While multiple clinical trials have evaluated Akt inhibition, Akt-targeted therapies directed in general have not been effective for mCRC…”
BackgroundHinoue, T., Weisenberger, D. J., Pan, F., Campan, M., Kim, M., Young, J., Whitehall, V. L., Leggett, B. A., & Laird, P. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008357 · Cited by 144
Gatalica, Z., Vranic, S., Xiu, J., Swensen, J., & Reddy, S. (2016) · Familial Cancer · doi:10.1007/s10689-016-9884-6 · Cited by 141
The Role of Src in Colon Cancer and Its Therapeutic Implications
Chen, J., Elfiky, A. A., Han, M., Chen, C., & Saif, M. W. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.10.003 · Cited by 139
Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer
Zhang, P., Kawakami, H., Liu, W., Zeng, X., Strebhardt, K., Tao, K., Huang, S., & Sinicrope, F. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0404 · Cited by 138
Ishaque, N., Abba, M. L., Hauser, C., Patil, N., Paramasivam, N., Huebschmann, D., Leupold, J. H., Balasubramanian, G. P., Kleinheinz, K., Toprak, U. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07041-z · Cited by 132 · cited 1×
“metastatic lesions vs corresponding primary tumors and normal samples in 12 mCRC patients.(10) In general there”
BackgroundPabla, B. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i5.133 · Cited by 125
Yakirevich, E., Resnick, M. B., Mangray, S., Wheeler, M., Jackson, C. L., Lombardo, K. A., Lee, J., Kim, K.-M., Gill, A. J., Wang, K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3000 · Cited by 121
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119 · cited 1×
“be monitored to provide an indication of resistance to antiEGFR therapy.(24) EGFR gene copy number and acquired”
BackgroundWei, Q., Ye, Z., Zhong, X. Y., Li, L., Wang, C., Myers, R. E., Palazzo, J., Fortuna, D., Yan, A., Waldman, S. A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx278 · Cited by 118
Mao, C., Liao, R.-Y., Qiu, L., Wang, X.-W., Ding, H., & Chen, Q. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0351-4 · Cited by 99
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice
Bekaii‐Saab, T., Kim, R. D., Kim, T. W., O’Connor, J. M., Strickler, J. H., Malka, D., Bianchi, A. S., Bi, F., Yamaguchi, K., Yoshino, T., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.11.002 · Cited by 88
Overview of Systemic Therapy for Colorectal Cancer
Goodwin, R. A., & Asmis, T. R. (2009) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0029-1242465 · Cited by 86
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taieb, J., Jung, A., Sartore-Bianchi, A., Peeters, M., Seligmann, J., Zaanan, A., Burdon, P., Montagut, C., & Laurent-Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 76
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 74
Kamal, Y., Schmit, S. L., Hoehn, H. J., Amos, C. I., & Frost, H. R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3945 · Cited by 73
The Tumor Microenvironment in Colorectal Cancer Therapy
Pedrosa, L., Esposito, F., Thomson, T. M., & Maurel, J. (2019) · Cancers · doi:10.3390/cancers11081172 · Cited by 69
Kayhanian, H., Goode, E., Sclafani, F., Ang, J. E., Gerlinger, M., de Castro, D. G., Shepherd, S. T. C., Peckitt, C., Rao, S., Watkins, D. J., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.006 · Cited by 67
Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy
Gozzi, G. J., Gonzalez, D., Boudesco, C., Dias, A. M. M., Gotthard, G., Uyanik, B., Dondaine, L., Marcion, G., Hermetet, F., Denis, C., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0343-4 · Cited by 66
Chemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine
Gmeiner, W. H. (2020) · Molecules · doi:10.3390/molecules25153438 · Cited by 66
Self-citationRevisiting the tumorigenesis timeline with a data-driven generative model
Lahouel, K., Younes, L., Danilova, L., Giardiello, F. M., Hruban, R. H., Groopman, J. D., Kinzler, K. W., Vogelstein, B., Geman, D., & Tomasetti, C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914589117 · Cited by 65
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
Foley, T. M., Payne, S. N., Pasch, C. A., Yueh, A. E., Van De Hey, D. R., Korkos, D. P., Clipson, L., Maher, M. E., Matkowskyj, K. A., Newton, M. A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0256 · Cited by 62
Murcia, Ó., Juárez, M., Soler, M. R., Hernández‐Illán, E., Giner-Calabuig, M., Alustiza, M., Egoavil, C. M., Castillejo, A., Alenda, C., Barberá, V. M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203051 · Cited by 53
Aasebø, K. Ø., Dragomir, A., Sundström, M., Mezheyeuski, A., Edqvist, P., Eide, G. E., Ponten, F., Pfeiffer, P., Glimelius, B., & Sorbye, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2205 · Cited by 51
Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers
Zhao, Y., Li, J., Li, D., Wang, Z., Zhao, J., Wu, X., Sun, Q., Lin, P. P., Plum, P. S., Damanakis, A. I., et al. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.026 · Cited by 50
Gmeiner, W. H. (2020) · Cancers · doi:10.3390/cancers12061641 · Cited by 50
Self-citationGenetic Alterations of Metastatic Colorectal Cancer
Testa, U., Castelli, G., & Pelosi, E. (2020) · Biomedicines · doi:10.3390/biomedicines8100414 · Cited by 44
Epidermal growth factor suppresses intestinal epithelial cell shedding via a MAPK dependent pathway.
Miguel, J. C., Maxwell, A. A., Hsieh, J. J., Harnisch, L. C., Alam, D. A., Polk, D. B., Lien, C., Watson, A. J. M., & Frey, M. R. (2016) · Journal of Cell Science · doi:10.1242/jcs.182584 · Cited by 43
Somarelli, J. A., Roghani, R. S., Moghaddam, A. S., Thomas, B. C., Rupprecht, G., Ware, K. E., Altunel, E., Mantyh, J. B., Kim, S. Y., McCall, S. J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0454 · Cited by 42
MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
Fricke, S. L., Payne, S. N., Favreau, P. F., Kratz, J. D., Pasch, C. A., Foley, T. M., Yueh, A. E., Van De Hey, D. R., Depke, M. G., Korkos, D. P., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0510 · Cited by 41
Battaglin, F., Puccini, A., Djaballah, S. A., & Lenz, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s186042 · Cited by 37
Clifton, K., Rich, T. A., Parseghian, C., Raymond, V. M., Dasari, A., Pereira, A. A. L., Willis, J., Loree, J. M., Bauer, T. M., Chae, Y. K., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00141 · Cited by 37
Siddiqui, A., Vazakidou, M. E., Schwab, A., Napoli, F., Molina, C. F., Rapa, I., Stemmler, M. P., Volante, M., Brabletz, T., & Ceppi, P. (2017) · The Journal of Pathology · doi:10.1002/path.4897 · Cited by 36
Allgayer, H., Leupold, J. H., & Patil, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.018 · Cited by 36
Saif, M. W., & Diasio, R. B. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3063-1 · Cited by 35
Ottaiano, A., Caraglia, M., Mauro, A. D., Botti, G., Lombardi, A., Galon, J., Luce, A., D’Amore, L., Perri, F., Santorsola, M., et al. (2020) · Cancers · doi:10.3390/cancers12103073 · Cited by 35
Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers.
Al-Shamsi, H. O., Alhazzani, W. A., & Wolff, R. A. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2015.016 · Cited by 34
Candidate genes involved in metastasis of colon cancer identified by integrated analysis
Zhou, Y., Zang, Y., Yang, Y., Xiang, J., & Chen, Z. (2019) · Cancer Medicine · doi:10.1002/cam4.2071 · Cited by 31
Wei, H., Li, J., Xie, M., Lei, R., & Hu, B.-L. (2018) · PeerJ · doi:10.7717/peerj.5433 · Cited by 29
Wang, Z.-X., Wu, H.-X., He, M.-M., Wang, Y.-N., Luo, H.-Y., Ding, P.-R., Xie, D., Chen, G., Li, Y.-H., Wang, F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7279 · Cited by 29 · cited 1×
“ciated with innate resistance to anti-EGFR therapy does not contraindicate their use.(21) However, biomarker screen-”
BackgroundKatholnig, K., Schütz, B., Fritsch, S. D., Schörghofer, D., Linke, M., Sukhbaatar, N., Matschinger, J. M., Unterleuthner, D., Hirtl, M., Lang, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124164 · Cited by 29
Haber, A. O., Jain, A., Mani, C., Nevler, A., Agostini, L. C., Golan, T., Palle, K., Yeo, C. J., Gmeiner, W. H., & Brody, J. R. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0985 · Cited by 23
Self-citationHuman Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer
Bianchi, A. S., Marsoni, S., & Siena, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3323 · Cited by 21
Gmeiner, W. H., Dominijanni, A., Haber, A. O., Ghiraldeli, L. P., Caudell, D. L., D’Agostino, R., Pasche, B. C., Smith, T. L., Deng, Z., Kiren, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0516 · Cited by 21
Self-citationGustavson, M. D., Molinaro, A. M., Tedeschi, G., Camp, R. L., & Rimm, D. L. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/132.11.1746 · Cited by 19
Clonal Evolution and Timing of Metastatic Colorectal Cancer
Siraj, S., Masoodi, T., Siraj, A. K., Azam, S., Qadri, Z., Ahmed, S. O., Albalawy, W. N., Alobaisi, K., Parvathareddy, S. K., AlManea, H. M., et al. (2020) · Cancers · doi:10.3390/cancers12102938 · Cited by 17
Redefining Colorectal Cancer by Tumor Biology
Salem, M. E., Puccini, A., & Tie, J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279867 · Cited by 14
Öhrling, K., Karlberg, M., Edler, D., Hallström, M., & Ragnhammar, P. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.11.003 · Cited by 10
Kang, M., Zheng, W., Chen, Q., Qin, W., Li, P., Huang, S., Zhou, Y., Wang, L., Cai, H., Lu, W., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.026 · Cited by 10
Wakatsuki, T., Stintzing, S., Zhang, W., Yang, D., Azuma, M., Ning, Y., Yamauchi, S., Matsusaka, S., Volz, N. B., Sunakawa, Y., et al. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000087 · Cited by 4
Research works printed but not linked: 2
- Gustavson, 2008, Arch Pathol Lab Med, 132, 1746, 10.1043/1543-2165-132.11.1746 · doi:10.1043/1543-2165-132.11.1746
- Salonga, 2000, Clin Cancer Res, 6, 1322
Cited by
Gmeiner, W. H., & Okechukwu, C. C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.136 · Cited by 125
Self-citationRise of the natural red pigment ‘prodigiosin’ as an immunomodulator in cancer
Anwar, M. M., Albanese, C., Hamdy, N. Μ., & Sultan, A. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02815-4 · Cited by 84
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
Self-citationA narrative review of genetic factors affecting fluoropyrimidine toxicity
Gmeiner, W. H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-17 · Cited by 25
Self-citationDing, Q., Sun, Y., Zhang, J., Yao, Y., Huang, D., & Jiang, Y. Y. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-797 · Cited by 25
Metadata
- Authors
- Gmeiner, W. H.
- Affiliations
- Wake Forest University Health Sciences (US)
- Corresponding author
- Gmeiner, William H
- ORCID
- Gmeiner, William H
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-03
- Volume
- Volume 14
- Pages
- 2121-2130
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC8007558
- OpenAlex
- W3139459873
- Cited by
- 18
- References
- 91
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 6 · 2021: 2
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Comprehensive Cancer Center at Wake Forest Baptist Medical Center (P30CA012197)
- National Institutes of Health (CA012197)
- National Cancer Institute (R21CA218933, P30CA012197)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- metastatic colorectal cancer, tumor biology, RAS mutations, microsatellite instability, intratumoral heterogeneity, intertumoral heterogeneity, personalized treatment, targeted therapy, exome sequencing, metastasis, molecular subtypes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.